John A Batsis1,2,3,4, Christian Haudenschild1,3, Robert M Roth1,5, Tyler L Gooding2, Meredith N Roderka2, Travis Masterson1, John Brand1, Matthew C Lohman6, Todd A Mackenzie1,2,3. 1. Geisel School of Medicine at Dartmouth, Hanover, NH. 2. Department of Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH. 3. The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH. 4. Division of Geriatric Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC. 5. Neuropsychology Program, Department of Psychiatry, Dartmouth-Hitchcock Medical Center, Lebanon, NH. 6. Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC.
Abstract
Objectives: The prevalence of obesity with sarcopenia is increasing in adults aged ≥65 years. This geriatric syndrome places individuals at risk for synergistic complications that leads to long-term functional decline. We ascertained the relationship between sarcopenic obesity and incident long-term impaired global cognitive function in a representative US population. Design: A longitudinal, secondary data set analysis using the National Health and Aging Trends Survey. Setting: Community-based older adults in the United States. Participants: Participants without baseline impaired cognitive function aged ≥65 years with grip strength and body mass index measures. Methods: Sarcopenia was defined using the Foundation for the National Institutes of Health Sarcopenia Project grip strength cut points (men <35.5 kg; women <20 kg), and obesity was defined using standard body mass index (BMI) categories. Impaired global cognition was identified as impairment in the Alzheimer's Disease-8 score or immediate/delayed recall, orientation, clock-draw test, date/person recall. Proportional hazard models ascertained the risk of impaired cognitive function over 8 years (referent = neither obesity or sarcopenia). Results: Of the 5822 participants (55.7% women), median age category was 75 to 80, and mean grip strength and BMI were 26.4 kg and 27.5 kg/m2, respectively. Baseline prevalence of sarcopenic obesity was 12.9%, with an observed subset of 21.2% participants having impaired cognitive function at follow-up. Compared with those without sarcopenia or obesity, the risk of impaired cognitive function was no different in obesity alone [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82-1.16]), but was significantly higher in sarcopenia (HR 1.60; 95% CI 1.42-1.80) and sarcopenic obesity (HR 1.20; 95% CI 1.03-1.40). There was no significant interaction term between sarcopenia and obesity. Conclusions: Both sarcopenia and sarcopenic obesity are associated with an increased long-term risk of impaired cognitive function in older adults.
Objectives: The prevalence of obesity with sarcopenia is increasing in adults aged ≥65 years. This geriatric syndrome places individuals at risk for synergistic complications that leads to long-term functional decline. We ascertained the relationship between sarcopenic obesity and incident long-term impaired global cognitive function in a representative US population. Design: A longitudinal, secondary data set analysis using the National Health and Aging Trends Survey. Setting: Community-based older adults in the United States. Participants: Participants without baseline impaired cognitive function aged ≥65 years with grip strength and body mass index measures. Methods: Sarcopenia was defined using the Foundation for the National Institutes of Health Sarcopenia Project grip strength cut points (men <35.5 kg; women <20 kg), and obesity was defined using standard body mass index (BMI) categories. Impaired global cognition was identified as impairment in the Alzheimer's Disease-8 score or immediate/delayed recall, orientation, clock-draw test, date/person recall. Proportional hazard models ascertained the risk of impaired cognitive function over 8 years (referent = neither obesity or sarcopenia). Results: Of the 5822 participants (55.7% women), median age category was 75 to 80, and mean grip strength and BMI were 26.4 kg and 27.5 kg/m2, respectively. Baseline prevalence of sarcopenic obesity was 12.9%, with an observed subset of 21.2% participants having impaired cognitive function at follow-up. Compared with those without sarcopenia or obesity, the risk of impaired cognitive function was no different in obesity alone [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82-1.16]), but was significantly higher in sarcopenia (HR 1.60; 95% CI 1.42-1.80) and sarcopenic obesity (HR 1.20; 95% CI 1.03-1.40). There was no significant interaction term between sarcopenia and obesity. Conclusions: Both sarcopenia and sarcopenic obesity are associated with an increased long-term risk of impaired cognitive function in older adults.
Authors: J A Batsis; T A Mackenzie; S J Bartels; K R Sahakyan; V K Somers; F Lopez-Jimenez Journal: Int J Obes (Lond) Date: 2015-12-01 Impact factor: 5.095
Authors: Laura L Ekblad; Juha O Rinne; Pauli Puukka; Hanna Laine; Satu Ahtiluoto; Raimo Sulkava; Matti Viitanen; Antti Jula Journal: Diabetes Care Date: 2017-04-05 Impact factor: 19.112